share_log

康恩贝(600572.SH):硫酸阿米卡星注射液药品通过仿制药一致性评

Zhejiang Conba Pharmaceutical (600572.SH): Amikacin Sulfate Injection pharmaceutical passed the generic drug consistency evaluation

Gelonghui Finance ·  Dec 3, 2024 00:42

Zhejiang Conba Pharmaceutical (600572.SH) announced on December 3 that the company has received the Drug Administration of China's approval for the issuance of the Approval Notice for the supplementary application of Amikacin Sulfate Injection (hereinafter referred to as "the pharmaceutical"), which has passed the evaluation of generic drug quality and efficacy consistency. Amikacin Sulfate is an aminoglycoside antibiotic, clinically applicable to severe infections caused by sensitive gram-negative rods such as Pseudomonas aeruginosa and other Pseudomonas species, Escherichia coli, and Staphylococcus species (methicillin-sensitive strains), such as septicemia or sepsis, bacterial endocarditis, etc.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment